Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
16 May 2024 - 11:16PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
________________________
Washington, D.C. 20549
_____________________
FORM 6-K
_____________________
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of May 2024
Commission File Number: 001-37835
________________________________________
Indivior PLC
________________________________________
10710 Midlothian Turnpike, Suite 125
North Chesterfield, Virginia 23235
(Address of principal executive office)
_______________________________
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F
Form
20-F ☒ Form 40-F ☐
EXHIBIT INDEX
|
Exhibit
No.
|
Description
of Exhibit
|
|
99.1
|
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
Indivior PLC
|
|
Date: May 16,
2024
|
/s/
Kathryn Hudson
|
|
|
Name:
Kathryn Hudson
|
|
|
Title:
Company Secretary
|
Exhibit 99.1
Indivior To Participate in Upcoming Investor Events
Slough, UK, and Richmond, VA, May 16, 2024 - Indivior PLC (LSE/NASDAQ: INDV) today announced
that it will participate in the following investor
events:
● 21st Annual
Craig-Hallum Institutional Investor Conference - Minneapolis,
MN
Indivior Management will host 1x1 / Group meetings
on Wednesday May 29th,
2024. Interested investors should contact their Craig-Hallum
representative to schedule a meeting.
● Jefferies Global Healthcare
Conference - New York City, NY
Mark Crossley, Chief Executive Officer, will host
a presentation on Wednesday June 5th,
2024 at 8:30 a.m. US EST. The presentation will be publicly
available and can be viewed using the following
weblink:
Webcast
link
About Indivior
Indivior is a global pharmaceutical company working to help change
patients' lives by developing medicines to treat substance use
disorders (SUD) and serious mental illnesses. Our vision is that
all patients around the world will have access to evidence-based
treatment for the chronic conditions and co-occurring disorders of
SUD. Indivior is dedicated to transforming SUD from a global human
crisis to a recognized and treated chronic disease. Building on its
global portfolio of opioid use disorder treatments, Indivior has a
pipeline of product candidates designed to both expand on its
heritage in this category and potentially address other chronic
conditions and cooccurring disorders of SUD. Headquartered in the
United States in Richmond, VA, Indivior employs more than 1,100
individuals globally and its portfolio of products is available in
37 countries worldwide. Visit www.indivior.com to learn
more. Connect with Indivior on LinkedIn by
visiting www.linkedin.com/company/indivior.
Contact:
Jason Thompson
Vice President, Investor Relations
Tel: 804-402-7123 or jason.thompson@indivior.com
Tim Owens
Director, Investor Relations
Tel: 804-263-3978 or timothy.owens@indivior.com
Indivior (PK) (USOTC:IZQVF)
Historical Stock Chart
From May 2024 to Jun 2024
Indivior (PK) (USOTC:IZQVF)
Historical Stock Chart
From Jun 2023 to Jun 2024
